[1] RALLI M,ANGELETTI D,FIORE M,et al.Hashimoto's thyroiditis:an update on pathogenic mechanisms,diagnostic protocols,therapeutic strategies,and potential malignant transformation[J].Autoimmun Rev,2020,19(10):102649.
[2] LI Y,TENG D,BA J,et al.Efficacy and safety of long-term universal salt iodization on thyroid disorders:epidemiological evidence from 31 provinces of Mainland China[J].Thyroid,2020,30(4):568-579.
[3] WEETMAN A P.An update on the pathogenesis of Hashimoto's thyroiditis[J].J Endocrinol Invest,2021,44(5):883-890.
[4] LU Q,LUO X,MAO C,et al.Caveolin-1 regulates autophagy activity in thyroid follicular cells and is involved in Hashimoto's thyroiditis disease[J].Endocr J,2018,65(9):893-901.
[5] LIU B,ZHENG T,DONG L,et al.Caveolin-1 regulates CCL5 and PPARγ expression in Nthy-ori 3-1 cells:possible involvement of Caveolin-1 and CCL5 in the pathogenesis of Hashimoto's Thyroiditis[J].Endocr Metab Immune Disord Drug Targets,2020,20(4):609-618.
[6] 葛均波,俆永健,王辰，等.内科学 [M].北京:人民卫生出版社,2018:694.
[7] HAN C,HE X,XIA X,et al.Sphk1/S1P/S1PR1 signaling is involved in the development of autoimmune thyroiditis in patients and NOD.H-2(h4) mice[J].Thyroid,2019,29(5):700-713.
[8] AJJAN R A,WEETMAN A P.The pathogenesis of Hashimoto's thyroiditis:further developments in our understanding[J].Horm Metab Res,2015,47(10):702-710.
[9] ZHOU Z,ZUO CL,LI X S,et al.Uterus globulin associated protein 1 (UGRP1) is a potential marker of progression of Graves' disease into hypothyroidism[J].Mol Cell Endocrinol,2019,494:110492.
[10] PARK S H,KIM M S,LIM H X,et al.IL-33-matured dendritic cells promote Th17 cell responses via IL-1β and IL-6[J].Cytokine,2017,99:106-113.
[11] INOUE N,WATANABE M,ISHIDO N,et al.Involvement of genes encoding apoptosis regulatory factors (FAS,FASL,TRAIL,BCL2,TNFR1 and TNFR2) in the pathogenesis of autoimmune thyroid diseases[J].Hum Immunol,2016,77(10):944-951.
[12] 李阿楠,张晓序,任翠平,等.白细胞介素-1β诱导甲状腺细胞凋亡机制的研究[J].安徽医科大学学报,2020,55(9):1385-1388.
[13] 张金淼,郝清静,江凯旋,等.鞘氨醇激酶2在肿瘤中的作用及其抑制剂研究进展[J].药学学报,2020,55(9):2062-2069.
[14] 程莎莎,程晖,张学军.神经酰胺在皮肤中的主要功能[J].中国麻风皮肤病杂志,2018,34(5):307-309.
[15] 张峥嵘,吴虹,戴丽,等.1-磷酸鞘氨醇及受体对自身免疫性疾病血管新生的影响[J].中国药理学通报,2017,33(9):1190-1194.
[16] ZHENG X,LI W,REN L,et al.The sphingosine kinase-1/sphingosine-1-phosphate axis in cancer:potential target for anticancer therapy[J].Pharmacol Ther,2019,195:85-99.
[17] ZAIBAQ F,DOWDY T,LARION M.Targeting the sphingolipid rheostat in gliomas[J].Int J Mol Sci,2022,23(16).9255.
[18] DONATI C,CENCETTI F,BERNACCHIONI C,et al.Role of sphingosine 1-phosphate signalling in tissue fibrosis[J].Cell Signal,2021,78:109861.
[19] ESCARCEGA R D,MCCULLOUGH L D,TSVETKOV A S.The functional role of sphingosine kinase2[J].Front Mol Biosci,2021,8:683767.
[20] NAGAHASHI M,TAKABE K,TERRACINA K P,et al.Sphingosine-1-phosphate transporters as targets for cancer therapy[J].Biomed Res Int,2014,2014:651727.
[21] LV L,YI Q,YAN Y,et al.SPNS2 downregulation induces EMT and promotes colorectal cancer metastasis via activating AKT signaling pathway[J].Front Oncol,2021,11:682773.
[22] 贲新宇,易西南,李其富.1-磷酸鞘氨醇及其信号传导在中枢神经系统疾病中的研究进展[J].海南医学院学报,2023,29(23):1825-1830，1835.
[23] BRAVO G Á,CEDEÑO R R,CASADEVALL M P,et al.Sphingosine-1-Phosphate (S1P) and S1P signaling pathway modulators,from current insights to future perspectives[J].Cells,2022,11(13):2058.
[24] MCGINLEY M P,COHEN J A.Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions[J].Lancet,2021,398(10306):1184-1194.
[25] LAI W Q,IRWAN A W,GOH H H,et al.Anti-inflammatory effects of sphingosine kinase modulation in inflammatory arthritis[J].J Immunol,2008,181(11):8010-8017.
[26] GARRIS C S,WU L,ACHARYA S,et al.Defective sphingosine 1-phosphate receptor 1 (S1P1) phosphorylation exacerbates TH17-mediated autoimmune neuroinflammation[J].Nat Immunol,2013,14(11):1166-1172.
[27] YAZDI A,GHASEMI-KASMAN M,JAVAN M.Possible regenerative effects of fingolimod (FTY720) in multiple sclerosis disease:an overview on remyelination process[J].J Neurosci Res,2020,98(3):524-536.
[28] LIU Y,YANG C L,YANG B,et al.Prophylactic administration of fingolimod (FTY720) ameliorated experimental autoimmune myasthenia gravis by reducing the number of dendritic cells,follicular T helper cells and antibody-secreting cells[J].Int Immunopharmacol,2021,96:107511.
[29] MOROHOSHI K,OSONE M,YOSHIDA K,et al.The sphingosine 1-phosphate receptor modulator FTY720 prevents iodide-induced autoimmune thyroiditis in non-obese diabetic mice[J].Autoimmunity,2011,44(6):490-495.
[30] BAKER D A,BARTH J,CHANG R,et al.Genetic sphingosine kinase 1 deficiency significantly decreases synovial inflammation and joint erosions in murine TNF-alpha-induced arthritis[J].J Immunol,2010,185(4):2570-2579.
[31] SPIEGEL S,MILSTIEN S.The outs and the ins of sphingosine-1-phosphate in immunity[J].Nat Rev Immunol,2011,11(6):403-415.
[32] MORAWSKA K,MACIEJCZYK M,ZIBA S,et al.Cytokine/Chemokine/Growth factor profiles contribute to understanding the pathogenesis of the salivary gland dysfunction in euthyroid hashimoto's thyroiditis patients[J].Mediators Inflamm,2021,2021:3192409.
[33] 李怡珂,张伟卫,王鹏,等.S1P与T淋巴细胞在主要免疫器官间迁移的关系[J].郑州大学学报(医学版),2023,58 (1):68-73.
[34] QIN J,SHEN X,ZHANG J,et al.Allosteric inhibitors of the STAT3 signaling pathway[J].Eur J Med Chem,2020,190:112122.
[35] SHIAH J V,GRANDIS J R,JOHNSON D E.Targeting STAT3 with proteolysis targeting chimeras and next-generation antisense oligonucleotides[J].Mol Cancer Ther,2021,20(2):219-228.
[36] HUANG L S,SUDHADEVI T,FU P,et al.Sphingosine kinase 1/S1P signaling contributes to pulmonary fibrosis by activating Hippo/YAP pathway and mitochondrial reactive oxygen species in lung fibroblasts[J].Int J Mol Sci,2020,21(6):2064-2086.
[37] ZHANG X,WANG W,JI X Y,et al.Knockout of sphingosine kinase 1 attenuates renal fibrosis in unilateral ureteral obstruction model[J].Am J Nephrol,2019,50(3):196-203.
[38] 张红,张正红,林凤屏,等.1-磷酸鞘氨醇在肾脏纤维化中的作用及其调控[J].生命的化学,2020,40 (1):32-36.
[39] THIERY J P,ACLOQUE H,HUANG R Y,et al.Epithelial-mesenchymal transitions in development and disease[J].Cell,2009,139(5):871-890.
[40] NAGAHASHI M,ABE M,SAKIMURA K,et al.The role of sphingosine-1-phosphate in inflammation and cancer progression[J].Cancer Sci,2018,109(12):3671-3678.
[41] XU S,HUANG H,QIAN J,et al.Prevalence of hashimoto thyroiditis in adults with papillary thyroid cancer and its association with cancer recurrence and outcomes[J].JAMA Netw Open,2021,4(7):e2118526.
[42] 魏铭泽,赵娜,李宏岳,等.甲状腺乳头状癌合并桥本甲状腺炎患者外周血T细胞亚群特征性的分析[J].东南大学学报(医学版),2020,39(3):341-347.
[43] 李洪跃,徐先发,杨晓琦,等.基于血清代谢标志物的甲状腺癌患者淋巴结转移风险的预测模型[J].现代医学,2022,50(5):581-588. |
